The efficacy and safety of setmelanotide in individuals with Bardet-Biedl syndrome or Alström syndrome: Phase 3 trial design

The efficacy and safety of setmelanotide in individuals with Bardet-Biedl syndrome or Alström syndrome: Phase 3 trial design

Background: A phase 2 trial has suggested that treatment with the melanocortin-4 receptor (MC4R) agonist setmelanotide is associated with a decrease in hunger and weight-related outcomes in participants with Bardet-Biedl syndrome (BBS) and Alström syndrome. Here, we present the study design of an on...

Full description

Bibliographic Details
Main Authors: Robert M. Haws, Gregory Gordon, Joan C. Han, Jack A. Yanovski, Guojun Yuan, Murray W. Stewart
Format: Article
Language:English
Published: Elsevier 2021-06-01
Series:Contemporary Clinical Trials Communications
Subjects:
Antiobesity drug
Appetite control
Obesity therapy
Phase III study
Online Access:http://www.sciencedirect.com/science/article/pii/S2451865421000818

Internet

http://www.sciencedirect.com/science/article/pii/S2451865421000818

Similar Items